This checklist for reproducibility of natural product research provides guidance for transparent reporting and scientific rigour of preclinical research as set out in A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: reproducibility of natural product research (Izzo et al., 2020). This checklist is intended as a guide for submission to the British Journal of Pharmacology. 这份天然产物研究可重复性清单提供了关于临床前研究的透明化报告和科学严谨性方面的指导, 并按照《英国药理学期刊针对天然产物研究透明化的操作指南:天然产物研究可重复性》(Izzo et al., 2020 年) 中所列出的要求。这份清单旨在为英国药理学期刊提交的稿件提供指导。
| Criteria 标准 | Number 编号 | Issue 问题 | Where to place the information 信息记录于何处 |
|---|---|---|---|
| BJP scope BJP 范围 | 1 | Identification of the possible mechanism of action of the natural product is mandatory, and this should be highlighted in the abstract. 必须在摘要中明确且强调天然产物的可能作用机制 | Abstract 摘要 |
| Compound purity 化合物纯度 | 2a | Purity of the compound (and major impurities) must be reported. 必须提供化合物 (和主要杂质)的纯度 | Methods 方法 |
| 2b | Papers on mixtures of compounds (e.g., herbal extracts) must be accompanied by evidence demonstrating similar activity of a purified component(s) of that extract and percentage of purity must be stated. 投稿中涉及到混合物 (例如草药提取物)必须附有证明该提取物的纯化成分具有类似活性的证据, 且须说明纯度百分比 | Methods and Results 方法和结果 | |
| Extract source and natural product preparation 提取源及天然产物制备 | 3a | Full details regarding the provenance and processing of extracts must be provided. 必须提供有关提取物来源和加工的完整细节 | Methods 方法 |
| 3b | The source of the product (i.e., country and region, from the wild or cultivated) should be reported. 必须提供天然产物来源信息 (例如国家, 地区, 野生或栽培) | Methods 方法 | |
| 3c | Extracts must be chemically characterized, and the content of component compound(s) must be measured with validated analytical methods. 提取物必须进行化学表征检测, 其有效成分含量必须用有效的分析方法进行测量 | Methods 方法 | |
| Vehicle effects 溶剂效应 | 4a | Vehicle effects must be clearly reported, with mean ± SEM or SD, appropriate statistic alanalysis and with n ≥ 5. 必须清楚溶剂本身效应, 采用平均值±SEM或SD、适当的统计分析和n ≥ 5的方式进行标示 | Results and Discussion 结果和讨论 |
| 4b | Reporting of the minimum concentration of vehicle required to enable solubilization is advised. 建议写出溶剂溶解药物的最低浓度 | Results 结果 | |
| 4c | The effect of the vehicle on the responses under study must be reported. 必须报告溶剂对所研究的生物学效应的影响 | Results 结果 | |
| 4d | In cases where the vehicle does affect the response being studied, concentration‐response curves for both the vehicle and the compound under investigation must be shown. 如果溶剂影响所研究的生物学效应, 则必须提供溶剂及所研究化合物的浓度‐反应曲线 | Results 结果 | |
| Positive control 阳性对照 | 5 | The effect of the compound under investigation should be compared with a clinically effective drug. If a positive control is not included, a valid scientific justification must be provided (e.g., there are no clinically effective drugs for the specific condition). The size of the effect in relation to the disease under evaluation must be discussed. 所研究化合物的效果应与临床有效药物进行比较。如未提供阳性对照, 则必须给予有效的科学依据 (例如, 针对特定临床情况, 尚无有效药物)。必须讨论其与所研究疾病的相关性 | Results and/or Discussion 结果和/或讨论 |
| Concentrations in vitro 体外实验浓度 | 6a | Rationale for the selection of concentrations used must be provided. 必须提供所用浓度的理由 | Methods 方法 |
| 6b | Pharmacokinetic data on plasma levels following systemic administration should be considered. 应考虑给药后血浆水平的药代动力学 | Results and/or Discussion 结果和/或讨论 | |
| 6c | Concentrations much higher than the IC50 or Ki reported for the compound underinvestigation must not be used. 不得使用远高于所研究化合物已报道的IC50或Ki的浓度 | Methods 方法 | |
| Doses in vivo 体内实验浓度 | 7 | The rationale for selection of the doses used must be provided. If testing as a potentialtherapeutic agent, relevance to the clinical setting must also be provided. 必须提供选择所用剂量的理由。如果测试作为一种潜在的治疗剂, 还必须提供与临床应用的相关性 | Methods 方法 |
| Route and timing of administration 给药方式及时间 | 8 | The rationale for the selection of the route, timing, and frequency of administration should be provided. 应提供选择给药途径、时间和频率的理由 | Methods 方法 |
| Toxicity 毒性 | 9 | Evidence of safety should be provided. If not available, potential toxicity should be discussed. 应提供安全证据。如不能提供, 则应讨论潜在毒性 | Results and/or Discussion 结果和/或讨论 |
| Adherence to BJP guidelines 遵守 BJP 指南 | 10 | BJP guidelines must be followed using the BJP Editorials as a reference (Alexander et al., 2018; Curtis et al.,2018; Docherty et al.,2019; George et al., 2017; George et al., 2019). Checklists are available on the BJP website. BJP 指南必须遵循 BJP 编者按 (Curtis 等人, 2018 年；George 等人, 2017年；George 等人, 2019年；Alexander 等人, 2018年；Docherty 等人, 2019年)。检查清单可在 BJP 网站上找到 | Methods and Results 方法和结果 |
N3,63?] ?>. Declaration of transparency and scientific rigour: Checklist for reproducibility of natural product research 透明化及科学严谨性声明: 天然产物研究可重复性清单. Br J Pharmacol. 2020;177:5006–5007. 10.1111/bph.15256